Loteprednol Etabonate
drugOn this page
Also known as AlrexCDDD 5604CDDD-5604CDDD5604EysuvisHGP-1InveltysKPI-121LotemaxLotemax smLoteprednolLoteprednol etabonate component of zyletP-5604SID170465195SID144205772C0164566
Summary
Loteprednol Etabonate (CHEMBL1200865) is an approved small-molecule anti-inflammatory drug (ATC S01BA14); indicated across 8 conditions including eye disorder and dry eye syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: S01BA14
- Indications: 8 conditions
- Clinical trials: 46
- Chemistry: 466.9 Da · C24H31ClO7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200865 |
| Name | Loteprednol Etabonate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 444025 |
| ChEBI | CHEBI:31784 |
| ATC | S01BA14 |
| Molecular formula | C24H31ClO7 |
| Molecular weight | 466.9 |
| InChIKey | DMKSVUSAATWOCU-HROMYWEYSA-N |
SMILES: CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl
IUPAC name: chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
Pharmacological roles (ChEBI): anti-inflammatory drug.
Also known as: Alrex, CDDD 5604, CDDD-5604, CDDD5604, Eysuvis, HGP-1, Inveltys, KPI-121, Lotemax, Lotemax sm, Loteprednol, Loteprednol etabonate
Patent coverage: 3,206 distinct patent families (11,414 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Glucocorticoid receptor, Progesterone receptor, Androgen receptor, Nuclear receptor subfamily 1 group I member 2, ATP-binding cassette sub-family C member 3, Bile salt export pump.
Bioactivity
ChEMBL activities: 5 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NR3C1 | 8.25 | AC50 | 5.6 | nM | CHEMBL_ACT_25176054 |
| PGR | 7.62 | AC50 | 24 | nM | CHEMBL_ACT_25223206 |
| NR1I2 | 5.61 | AC50 | 2440 | nM | CHEMBL_ACT_25224444 |
| P15207 | 5.58 | AC50 | 2600 | nM | CHEMBL_ACT_25232420 |
| NR1I2 | 5.57 | AC50 | 2700 | nM | CHEMBL_ACT_25188333 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| eye disorder | 4 | MONDO:0005328 | EFO:0005752 |
| dry eye syndrome | 4 | MONDO:0006733 | EFO:1000906 |
| atopic conjunctivitis | 4 | MONDO:0005642 | EFO:0007141 |
| anterior uveitis | 4 | MONDO:0006651 | EFO:1000811 |
| cataract | 3 | MONDO:0005129 | MONDO:0005129 |
| blepharitis | 2 | MONDO:0004785 | EFO:0009536 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 46.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 23 |
| PHASE3 | 12 |
| Not specified | 5 |
| PHASE2 | 3 |
| PHASE1 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00366691 | PHASE4 | COMPLETED | Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation |
| NCT00407043 | PHASE4 | COMPLETED | Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis |
| NCT00420628 | PHASE4 | COMPLETED | Pediatric Zylet Safety and Efficacy Study |
| NCT00447577 | PHASE4 | COMPLETED | Zylet vs TobraDex in Blepharokeratoconjunctivitis |
| NCT00532961 | PHASE4 | COMPLETED | Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex |
| NCT00689078 | PHASE4 | COMPLETED | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model |
| NCT00705159 | PHASE4 | COMPLETED | Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis |
| NCT00781300 | PHASE4 | COMPLETED | Intraocular Pressure With Loteprednol and Dexamethasone |
| NCT00817557 | PHASE4 | UNKNOWN | Use of Loteprednol for Contact Lens Intolerance and Dryness |
| NCT01193504 | PHASE4 | UNKNOWN | Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification |
| NCT01437982 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% |
| NCT01443442 | PHASE4 | COMPLETED | Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis |
| NCT01456780 | PHASE4 | COMPLETED | Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis |
| NCT01724892 | PHASE4 | COMPLETED | Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing |
| NCT01853696 | PHASE4 | COMPLETED | Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty |
| NCT02028312 | PHASE4 | WITHDRAWN | A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis® |
| NCT02120079 | PHASE4 | COMPLETED | The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED |
| NCT02974387 | PHASE4 | UNKNOWN | Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study |
| NCT03123614 | PHASE4 | COMPLETED | Loteprednol vs. Prednisolone and Fluorometholone |
| NCT04555694 | PHASE4 | COMPLETED | Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax |
| NCT05136443 | PHASE4 | COMPLETED | Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection |
| NCT07090044 | PHASE4 | COMPLETED | Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period |
| NCT07496060 | PHASE4 | COMPLETED | Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas |
| NCT00699153 | PHASE3 | COMPLETED | Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery |
| NCT01010633 | PHASE3 | COMPLETED | Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery |
| NCT01028027 | PHASE3 | COMPLETED | Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis |
| NCT01060072 | PHASE3 | COMPLETED | Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery |
| NCT01435460 | PHASE3 | COMPLETED | Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC) |
| NCT01475643 | PHASE3 | COMPLETED | Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children. |
| NCT02163824 | PHASE3 | COMPLETED | Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation |
| NCT02793817 | PHASE3 | COMPLETED | Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain |
| NCT02813265 | PHASE3 | COMPLETED | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease |
| NCT02819284 | PHASE3 | COMPLETED | Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease |
| NCT03596723 | PHASE3 | TERMINATED | KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children |
| NCT05322148 | PHASE3 | COMPLETED | Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization |
| NCT01817582 | PHASE2 | COMPLETED | Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) |
| NCT02188160 | PHASE2 | COMPLETED | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease |
| NCT02218489 | PHASE2 | COMPLETED | Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease |
| NCT03098953 | PHASE1 | COMPLETED | Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations |
| NCT05353101 | PHASE1 | COMPLETED | Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).